Trials / Recruiting
RecruitingNCT04578652
Fiber and Metformin Combination Therapy in Adolescents With Severe Obesity and Insulin Resistance
Fiber Supplementation and Metformin Combination Therapy in Adolescents With Severe Obesity and Insulin Resistance: Interactions With the Gut Microbiome.
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- University of Alberta · Academic / Other
- Sex
- All
- Age
- 12 Years – 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a 12-month, single center, three-arm parallel design, double-blind, randomized clinical trial, to compare the effects of supplemental dietary fiber and metformin (MET) alone and in combination over 12 months on glucose metabolism (insulin resistance \[IR\]), inflammation and BMI in adolescents with obesity and IR, and to assess the relationship between therapeutic intervention(s) and changes in gut microbiome composition and function. Since MET and FIBER have been shown to reduce weight and increase insulin sensitivity through distinct but overlapping mechanisms of action, our central hypothesis is that the combination of FIBER + MET will have a synergistic effect and be more effective than FIBER or MET alone in improving metabolic function (IR) and reducing BMI and inflammation in adolescents with obesity, IR and family history (FM) of T2DM. .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Metformin 850 mg oral tablet bid | MET dose: 500 mg daily, increasing to 500 bid if tolerated after 2 weeks, then increasing again 2 weeks later to 850 mg bid (1700 mg daily). |
| DIETARY_SUPPLEMENT | Supplemental fiber mixture (35 g total) composed of 6g of Oligofructose + 12g of resistant maltodextrin + 12g of acacia gum + 5g of PGX. | The first week of treatment will use 1/3 the daily treatment dose; then 2/3 dose for the second and third weeks; then the full dose thereafter, to allow time for adaptation. |
Timeline
- Start date
- 2021-10-22
- Primary completion
- 2026-09-01
- Completion
- 2026-09-01
- First posted
- 2020-10-08
- Last updated
- 2025-11-17
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT04578652. Inclusion in this directory is not an endorsement.